QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024Quartr·Aug 12 at 06:25 PMAKYA0.00%QTRX+4.26%
Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q SummaryTradingView·Aug 10 at 12:41 PMQTRX+4.26%AKYA0.00%
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026 | QTRX Stock NewsStockTitan·Apr 24 at 04:35 AMQTRX+4.26%
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 | QTRX Stock NewsStockTitan·Feb 20 at 05:33 AMQTRX+4.26%AKYA0.00%
Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | QTRX Stock NewsStockTitan·Jul 8, 2025 at 01:07 PMAKYA0.00%QTRX+4.26%
18:18 ET AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAprnewswire·Jun 20, 2025 at 10:19 PMAKYA0.00%
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal | AKYA Stock NewsStockTitan·May 23, 2025 at 06:21 PMAKYA0.00%QTRX+4.26%
Akoya Biosciences reveals Q1 2025 financial performance with promising numbers.Unusual Whales·May 12, 2025 at 08:28 PMAKYA0.00%
Akoya Biosciences | 8-K: FY2025 Q1 Revenue Misses Estimate at USD 16.64 MEarnings Watch·May 12, 2025 at 08:11 PMAKYA0.00%
